Algernon Pharmaceuticals Inc (CSE:AGN) (FRA:AGW) (OTCQB:AGNPF) has announced that all of the required permits and licenses for the manufacture of its AP-188 (N, N-Dimethyltryptamine or DMT) have been received.
As a result, the company said it is targeting its Phase 1 human study to be conducted at Hammersmith Medicines Research in the UK in the fourth quarter of 2021.
Algernon said it awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of DMT to Canada-based Dalton Pharma Services.
READ: Algernon Pharmaceuticals expands Ifenprodil research to pancreatic cancer in new clinical study
The Vancouver-based company said the planned Phase 1 study will investigate the safety, tolerability, and pharmacokinetics of intravenous DMT infusion in healthy volunteers with no prior history of psychedelic exposure. Specifically, the trial will aim to identify a sub-hallucinogenic dosing regimen to support planned clinical studies in stroke patients.
Meanwhile, Algernon also announced that its first preclinical study with research-grade DMT is now underway with Charles River Laboratories. The site in Kuopio, Finland is recognized as a world leader for preclinical stroke studies.
The company said the in vitro experiments will provide information on the duration and dose of infusion needed to achieve maximal cortical neurite outgrowth as well as the underlying mechanism of the drug’s action. These experiments will also inform the design of confirmatory animal stroke studies also planned at Charles River and scheduled for later this year.
“While there are many companies that are working in or attempting to enter the psychedelic drug space, many are a considerable distance from human studies,” said Algernon CEO Christopher Moreau in a statement. “We announced that we plan to be the first company globally to investigate DMT for stroke and that is a goal that we are getting closer to achieving.”
Algernon has filed provisional patents for new forms of DMT, in addition to formulation, dosage, and method of use claims for ischemic stroke. The company has also filed claims for combination therapy of DMT and Constraint-Induced Movement Therapy.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
pathogens and gives you more
energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video)
Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.